The role of renin angiotensin system inhibition in kidney repair

Fibrogenesis and Tissue Repair

Volumn 3, Issue 1, 2010, Pages

  Van der Meer, Irene M ^a,b,c   Cravedi, Paolo ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; METOPROLOL; PARICALCITOL; PERINDOPRIL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; RAMIPRIL; RENIN; RENIN INHIBITOR; RITUXIMAB; SPIRONOLACTONE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D;

ALBUMINURIA; BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GENE EXPRESSION REGULATION; GENE REPRESSION; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; HYPERTROPHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY STRUCTURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEINURIA; REGULATORY MECHANISM; REMISSION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; REVIEW; TISSUE REPAIR; TREATMENT RESPONSE;

EID: 79953679370     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-3-7     Document Type: Review

References (114)

1. Dirks JRG, Horton S, Schieppati A, Rizvi SAH. Diseases of the kidney and the urinary system. Disease Control Priorities in Developing Countries 2006, 695-706. New York: Oxford University Press and The World Bank.
2. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981, 241:F85-93.
3. Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov 2008, 7:936-953. 10.1038/nrd2685, 18846102.
4. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288-296. 10.1172/JCI27699, 1359063, 16453013.
5. Hostetter TH. Progression of renal disease and renal hypertrophy. Annu Rev Physiol 1995, 57:263-278. 10.1146/annurev.ph.57.030195.001403, 7778868.
6. Denton KM, Anderson WP, Sinniah R. Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole. Am J Physiol Regul Integr Comp Physiol 2000, 279:R629-638.
7. Ma LJ, Fogo AB. Modulation of glomerulosclerosis. Semin Immunopathol 2007, 29:385-395. 10.1007/s00281-007-0087-y, 17828397.
8. Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S, Bonomelli M, Mundel P, Endlich K, Remuzzi A, Remuzzi G. Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol 2006, 168:1073-1085. 10.2353/ajpath.2006.050701, 1606571, 16565484.
9. Bazzi C, Petrini C, Rizza V, Arrigo G, D'Amico G. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 2000, 58:1732-1741. 10.1046/j.1523-1755.2000.00334.x, 11012907.
10. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997, 46(Suppl 2):S104-111.
11. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996, 335:1636-1642. 10.1056/NEJM199611283352203, 8929360.
12. Nelson RG, Meyer TW, Myers BD, Bennett PH. Clinical and pathological course of renal disease in non-insulin-dependent diabetes mellitus: the Pima Indian experience. Semin Nephrol 1997, 17:124-131.
13. Johnson DW, Saunders HJ, Baxter RC, Field MJ, Pollock CA. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int 1998, 54:747-757. 10.1046/j.1523-1755.1998.00048.x, 9734599.
14. Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006, 20:217-226. 10.1096/fj.05-4747com, 16449793.
15. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002, 8:582-587. 10.1038/nm0602-582, 12042808.
16. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage?. J Am Soc Nephrol 2006, 17:2974-2984. 10.1681/ASN.2006040377, 17035611.
17. Kim HJ, Moradi H, Yuan J, Norris K, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol 2009, 296:F1297-1306. 10.1152/ajprenal.90761.2008, 19357177.
18. Schlondorff DO. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int 2008, 74:860-866. 10.1038/ki.2008.351, 18650795.
19. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 2001, 37:S25-29. 10.1053/ajkd.2001.20735, 11158857.
20. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010, 21:212-222. 10.1681/ASN.2008121226, 20019167.
21. Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008, 172:299-308. 10.2353/ajpath.2008.070057, 2312375, 18202193.
22. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939-945. 10.1056/NEJM199604113341502, 8596594.
23. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349:1857-1863. 10.1016/S0140-6736(96)11445-8, 9217756.
24. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364. 10.1016/S0140-6736(98)10363-X, 10437863.
25. Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, de Zeeuw D, Remuzzi G, Kamper AL, Levey AS. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007, 18:1959-1965. 10.1681/ASN.2006101081, 17475813.
26. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linne T. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007, 18:1880-1888. 10.1681/ASN.2006040347, 17513327.
27. Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, Remuzzi G. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis 2000, 35:381-391. 10.1016/S0272-6386(00)70190-9, 10692263.
28. Wei A, Burns GC, Williams BA, Mohammed NB, Visintainer P, Sivak SL. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003, 64:1462-1471. 10.1046/j.1523-1755.2003.00230.x, 12969167.
29. Deegens JK, Steenbergen EJ, Wetzels JF. Review on diagnosis and treatment of focal segmental glomerulosclerosis. Neth J Med 2008, 66:3-12.
30. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001, 12:2832-2837.
31. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354:131-140. 10.1056/NEJMoa053107, 16407508.
32. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2009, DOI: 10.1093/ndt/gfp511.
33. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355:253-259. 10.1016/S0140-6736(99)12323-7, 10675071.
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462. 10.1056/NEJM199311113292004, 8413456.
35. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878. 10.1056/NEJMoa011489, 11565519.
36. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. 10.1056/NEJMoa011161, 11565518.
37. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860. 10.1056/NEJMoa011303, 11565517.
38. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951. 10.1056/NEJMoa042167, 15516697.
39. Parving HH, Chaturvedi N, Viberti G, Mogensen CE. Does microalbuminuria predict diabetic nephropathy?. Diabetes Care 2002, 25:406-407. 10.2337/diacare.25.2.406, 11815526.
40. Parving HH, Mauer M, Ritz E. Diabetic Nephropathy. Brenner and Rector's The Kidney 2007, 1265. Philadelphia, PA: WB Saunders, 8.
41. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007, 18:1889-1898. 10.1681/ASN.2006121372, 17494885.
42. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1961. 10.1056/NEJMoa042274, 15516696.
43. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, Marion J. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000, 58:762-769. 10.1046/j.1523-1755.2000.00224.x, 10916100.
44. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444. 10.1136/bmj.321.7274.1440, 27545, 11110735.
45. Ruggenenti P, Cravedi P, Remuzzi G. Proteinuria: Increased angiotensin-receptor blocking is not the first option. Nat Rev Nephrol 2009, 5:367-368. 10.1038/nrneph.2009.77, 19556990.
46. Retraction--combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009, 374:1226. 10.1016/S0140-6736(09)61768-2, 19819378.
47. Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008, 52:475-485. 10.1053/j.ajkd.2008.03.008, 18468748.
48. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008, 19:1213-1224. 10.1681/ASN.2007090970, 2396935, 18354029.
49. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553. 10.1016/S0140-6736(08)61236-2, 18707986.
50. Ruggenenti P, Remuzzi G. Proteinuria: Is the ONTARGET renal substudy actually off target?. Nat Rev Nephrol 2009, 5:436-437. 10.1038/nrneph.2009.109, 19639016.
51. Gault MH, Fernandez D. Stable renal function in insulin-dependent diabetes mellitus 10 years after nephrotic range proteinuria. Nephron 1996, 72:86-92. 10.1159/000188812, 8903867.
52. McGregor D, Bailey RR. Over 11 years of stable renal function after remission of nephrotic-range proteinuria in type I diabetics treated with an ACE inhibitor. Nephron 1997, 76:270-275. 10.1159/000190191, 9226226.
53. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 1994, 46:1688-1693. 10.1038/ki.1994.469, 7700028.
54. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, Bain RP. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999, 34:308-314. 10.1016/S0272-6386(99)70360-4, 10430979.
55. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999, 10:997-1006.
56. Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 2009, 120:419-428. 2744545, 19768194.
57. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003, 14:2833-2842. 10.1097/01.ASN.0000095248.91994.D3, 14569093.
58. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003, 14:1132-1144. 10.1097/01.ASN.0000060574.38107.3B, 12707384.
59. Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 2005, 67:1913-1924. 10.1111/j.1523-1755.2005.00290.x, 15840039.
60. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991, 40:195-202. 10.1038/ki.1991.200, 1942767.
61. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005, 16:966-976. 10.1681/ASN.2004060492, 15728787.
62. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000, 58:2425-2436. 10.1046/j.1523-1755.2000.00426.x, 11115076.
63. Marinides GN, Groggel GC, Cohen AH, Border WA. Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int 1990, 37:749-757. 10.1038/ki.1990.42, 2407887.
64. Remuzzi A, Fassi A, Bertani T, Perico N, Remuzzi G. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis 1999, 34:626-632. 10.1016/S0272-6386(99)70385-9, 10516341.
65. Remuzzi A, Gagliardini E, Donadoni C, Fassi A, Sangalli F, Lepre MS, Remuzzi G, Benigni A. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002, 62:885-894. 10.1046/j.1523-1755.2002.00526.x, 12164870.
66. Remuzzi A, Gagliardini E, Sangalli F, Bonomelli M, Piccinelli M, Benigni A, Remuzzi G. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 2006, 69:1124-1130. 10.1038/sj.ki.5000060, 16395266.
67. Teles F, Machado FG, Ventura BH, Malheiros DM, Fujihara CK, Silva LF, Zatz R. Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int 2009, 75:72-79. 10.1038/ki.2008.528, 18946500.
68. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002, 13:2898-2908. 10.1097/01.ASN.0000034912.55186.EC, 12444208.
69. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75. 10.1056/NEJM199807093390202, 9654536.
70. Ohtake T, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Kobayashi S. Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. Hypertens Res 2008, 31:387-394. 10.1291/hypres.31.387, 18497456.
71. Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FI. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 1998, 47:12-15. 10.1016/S0026-0495(98)90364-X, 9867064.
72. Rudberg S, Osterby R, Bangstad HJ, Dahlquist G, Persson B. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with type I (insulin-dependent) diabetes mellitus. Diabetologia 1999, 42:589-595. 10.1007/s001250051199, 10333052.
73. Ahmad J, Shafique S, Abidi SM, Parwez I. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract 2003, 60:131-138. 10.1016/S0168-8227(03)00016-0, 12706322.
74. Perrin NE, Jaremko GA, Berg UB. The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial. Pediatr Nephrol 2008, 23:947-954. 10.1007/s00467-008-0745-x, 18270751.
75. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51. 10.1056/NEJMoa0808400, 19571282.
76. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes 2001, 50:843-850. 10.2337/diabetes.50.4.843, 11289051.
77. Cordonnier DJ, Pinel N, Barro C, Maynard M, Zaoui P, Halimi S, Hurault de Ligny B, Reznic Y, Simon D, Bilous RW. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 1999, 10:1253-1263.
78. White KE, Pinel N, Cordonnier DJ, Bilous RW. Does ACE inhibition slow progression of glomerulopathy in patients with Type 2 diabetes mellitus?. Diabet Med 2001, 18:933-936. 10.1046/j.1464-5491.2001.00607.x, 11703440.
79. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005, 16:3306-3314. 10.1681/ASN.2004090804, 16192423.
80. Jain G, Campbell RC, Warnock DG. Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1685-1691. 10.2215/CJN.01340209, 19729430.
81. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51:199-211. 10.1053/j.ajkd.2007.10.040, 18215698.
82. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4:542-551. 10.2215/CJN.04750908, 2653663, 19261819.
83. Cravedi P, Brusegan V, Ruggenenti P, Campbell R, Remuzzi G. Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: does it really work?. Pharmaceuticals 2010, 3:1-9.
84. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52:130-136. 10.1161/HYPERTENSIONAHA.107.108845, 18490518.
85. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007, 50:2398-2404. 10.1007/s00125-007-0795-9, 17828524.
86. Whaley-Connell A, Nistala R, Habibi J, Hayden MR, Schneider RI, Johnson MS, Tilmon R, Rehmer N, Ferrario CM, Sowers JR. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 298:F655-661. 10.1152/ajprenal.00373.2009, 20007350.
87. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446. 10.1056/NEJMoa0708379, 18525041.
88. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238. 151055, 12122115.
89. Valdivielso JM, Cannata-Andia J, Coll B, Fernandez E. A new role for vitamin D receptor activation in chronic kidney disease. Am J Physiol Renal Physiol 2009, 297:F1502-1509. 10.1152/ajprenal.00130.2009, 19625376.
90. de Zeeuw D, Agarwal R, Amdahl M, Andress D, Audhya P, Coyne D, Garimella T, Parving H, Pritchett Y, Remuzzi G, Ritz E. Selective Vitamin D Receptor Activator (VDRA) for Albuminuria Lowering (VITAL) Study in Type 2 diabetic nephropathy. J Am Soc Nephrol 2009, (20)., http://www.asn-online.org/education_and_meetings/renal_week/archives/
91. Langham RG, Kelly DJ, Gow RM, Zhang Y, Cordonnier DJ, Pinel N, Zaoui P, Gilbert RE. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care 2006, 29:2670-2675. 10.2337/dc06-0911, 17130203.
92. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006, 17:2999-3012. 10.1681/ASN.2006050503, 17035608.
93. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000, 58:251-259. 10.1046/j.1523-1755.2000.00160.x, 10886570.
94. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996, 7:653-660.
95. Macconi D, Ghilardi M, Bonassi ME, Mohamed EI, Abbate M, Colombi F, Remuzzi G, Remuzzi A. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol 2000, 11:477-489.
96. Liang XB, Ma LJ, Naito T, Wang Y, Madaio M, Zent R, Pozzi A, Fogo AB. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 2006, 17:1886-1895. 10.1681/ASN.2005020205, 16790514.
97. Macconi D, Sangalli F, Bonomelli M, Conti S, Condorelli L, Gagliardini E, Remuzzi G, Remuzzi A. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol 2009, 174:797-807. 10.2353/ajpath.2009.080227, 2665741, 19164508.
98. Wolf G, Ziyadeh FN, Zahner G, Stahl RA. Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 1996, 27:897-905.
99. Kale S, Karihaloo A, Clark PR, Kashgarian M, Krause DS, Cantley LG. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest 2003, 112:42-49. 162291, 12824456.
100. Poulsom R, Forbes SJ, Hodivala-Dilke K, Ryan E, Wyles S, Navaratnarasah S, Jeffery R, Hunt T, Alison M, Cook T, et al. Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 2001, 195:229-235. 10.1002/path.976, 11592103.
101. Feng Z, Plati AR, Cheng QL, Berho M, Banerjee A, Potier M, Jy WC, Koff A, Striker LJ, Striker GE. Glomerular aging in females is a multi-stage reversible process mediated by phenotypic changes in progenitors. Am J Pathol 2005, 167:355-363. 1603557, 16049323.
102. Fogo AB. New capillary growth: a contributor to regression of sclerosis?. Curr Opin Nephrol Hypertens 2005, 14:201-203. 10.1097/01.mnh.0000165883.08675.ab, 15821410.
103. Ito T, Suzuki A, Imai E, Okabe M, Hori M. Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. J Am Soc Nephrol 2001, 12:2625-2635.
104. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, Rottoli D, Angioletti S, Benigni A, Perico N, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004, 15:1794-1804. 10.1097/01.ASN.0000128974.07460.34, 15213267.
105. Bussolati B, Tetta C, Camussi G. Contribution of stem cells to kidney repair. Am J Nephrol 2008, 28:813-822. 10.1159/000137681, 18535367.
106. Lazzeri E, Crescioli C, Ronconi E, Mazzinghi B, Sagrinati C, Netti GS, Angelotti ML, Parente E, Ballerini L, Cosmi L, et al. Regenerative potential of embryonic renal multipotent progenitors in acute renal failure. J Am Soc Nephrol 2007, 18:3128-3138. 10.1681/ASN.2007020210, 17978305.
107. Romagnani P. Toward the identification of a "renopoietic system"?. Stem Cells 2009, 27:2247-2253. 10.1002/stem.140, 19739254.
108. Challen GA, Bertoncello I, Deane JA, Ricardo SD, Little MH. Kidney side population reveals multilineage potential and renal functional capacity but also cellular heterogeneity. J Am Soc Nephrol 2006, 17:1896-1912. 10.1681/ASN.2005111228, 16707564.
109. Sagrinati C, Ronconi E, Lazzeri E, Lasagni L, Romagnani P. Stem-cell approaches for kidney repair: choosing the right cells. Trends Mol Med 2008, 14:277-285. 10.1016/j.molmed.2008.05.005, 18554984.
110. Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D'Agati V, Alpers CE. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000, 58:674-683. 10.1046/j.1523-1755.2000.00213.x, 10916090.
111. Lin F, Moran A, Igarashi P. Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest 2005, 115:1756-1764. 10.1172/JCI23015, 1159127, 16007252.
112. Maeshima A, Yamashita S, Nojima Y. Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. J Am Soc Nephrol 2003, 14:3138-3146. 10.1097/01.ASN.0000098685.43700.28, 14638912.
113. Oliver JA, Maarouf O, Cheema FH, Martens TP, Al-Awqati Q. The renal papilla is a niche for adult kidney stem cells. J Clin Invest 2004, 114:795-804. 516259, 15372103.
114. Little MH. Regrow or repair: potential regenerative therapies for the kidney. J Am Soc Nephrol 2006, 17:2390-2401. 10.1681/ASN.2006030218, 16870708.